{"filing": {"accession": "0001493152-26-037971", "cik": "0001763950", "ticker": "LTRN", "company_name": "Lantern Pharma Inc.", "form_type": "10-Q", "filing_type": "10-Q", "filing_date": "2026-08-14", "accepted_datetime": null, "acceptance_datetime": null, "accepted_at": null, "primary_doc_url": "https://www.sec.gov/Archives/edgar/data/1763950/000149315226037971/0001493152-26-037971-index.htm", "filing_url": "https://www.sec.gov/Archives/edgar/data/1763950/000149315226037971/0001493152-26-037971-index.htm", "period_of_report": "2026-06-30"}, "html_url": "/api/filings/000149315226037971/stream", "exhibits": [{"exhibit_number": "31.1", "exhibit_type": "31", "description": "Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.", "filename": "ex31-1.htm", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1763950/000149315226037971/ex31-1.htm", "category": "other", "incorporated_by_reference": false}, {"exhibit_number": "31.2", "exhibit_type": "31", "description": "Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.", "filename": "ex31-2.htm", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1763950/000149315226037971/ex31-2.htm", "category": "other", "incorporated_by_reference": false}, {"exhibit_number": "32.1", "exhibit_type": "32", "description": "Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.", "filename": "ex32-1.htm", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1763950/000149315226037971/ex32-1.htm", "category": "other", "incorporated_by_reference": false}, {"exhibit_number": "32.2", "exhibit_type": "32", "description": "Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.", "filename": "ex32-2.htm", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1763950/000149315226037971/ex32-2.htm", "category": "other", "incorporated_by_reference": false}, {"exhibit_number": "3.1", "exhibit_type": "3", "description": "Amended and Restated Certificate of Incorporation", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1763950/000121390020015132/ea123112ex3-1v_lantern.htm", "category": "incorporation", "incorporated_by_reference": true}, {"exhibit_number": "3.2", "exhibit_type": "3", "description": "By-Laws", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1763950/000121390020009332/ea120601fs1ex3-1iv_lantern.htm", "category": "incorporation", "incorporated_by_reference": true}, {"exhibit_number": "3.3", "exhibit_type": "3", "description": "Amendment No. 1 to By-Laws", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1763950/000149315224021353/ex3-2.htm", "category": "incorporation", "incorporated_by_reference": true}, {"exhibit_number": "3.4", "exhibit_type": "3", "description": "Amendment No. 2 to By-Laws", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1763950/000164117225021407/ex3-2.htm", "category": "incorporation", "incorporated_by_reference": true}, {"exhibit_number": "4.1", "exhibit_type": "4", "description": "Form of Pre-Funded Common Stock Purchase Warrant", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1763950/000149315226023200/ex4-1.htm", "category": "debt", "incorporated_by_reference": true}, {"exhibit_number": "4.2", "exhibit_type": "4", "description": "Form of Purchase Warrant", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1763950/000149315226023200/ex4-2.htm", "category": "debt", "incorporated_by_reference": true}, {"exhibit_number": "4.3", "exhibit_type": "4", "description": "Form of Placement Agent Warrant", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1763950/000149315226023200/ex4-3.htm", "category": "debt", "incorporated_by_reference": true}, {"exhibit_number": "10.1", "exhibit_type": "10", "description": "Securities Purchase Agreement", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1763950/000149315226023200/ex10-1.htm", "category": "contracts", "incorporated_by_reference": true}], "sections": [{"section_name": "part_1", "section_title": "Part I", "start_position": 2693, "end_position": 3661}, {"section_name": "part_2", "section_title": "Part II", "start_position": 3661, "end_position": 3695}, {"section_name": "item_1a", "section_title": "Risk Factors", "start_position": 3695, "end_position": 114626}], "tables": [{"table_index": 0, "table_type": "text", "caption": null, "header_text": "Delaware001-3931846-3973463"}, {"table_index": 1, "table_type": "text", "caption": null, "header_text": "1920\n McKinney Avenue,7th FloorDallas,Texas75201"}, {"table_index": 2, "table_type": "text", "caption": null, "header_text": "Title\n of each classTrading\n SymbolName\n of each exchange on which registered"}, {"table_index": 3, "table_type": "text", "caption": null, "header_text": "Large\n accelerated filer\u2610Accelerated\n filer\u2610"}, {"table_index": 6, "table_type": "financial", "caption": null, "header_text": "Page"}, {"table_index": 9, "table_type": "financial", "caption": null, "header_text": "\u25cfthe\n existence of substantial doubt regarding our ability to continue as a going concern in the absence of obtaining substantial additional\n funding;"}, {"table_index": 12, "table_type": "text", "caption": null, "header_text": "\u25cfour\n ability to source our needs for skilled labor in the fields of artificial intelligence, genomics, biology, oncology and drug development;\n and"}, {"table_index": 15, "table_type": "financial", "caption": null, "header_text": "June\n 30, 2026December\n 31, 2025"}, {"table_index": 18, "table_type": "financial", "caption": null, "header_text": "2026202520262025"}, {"table_index": 21, "table_type": "text", "caption": null, "header_text": "2026202520262025"}, {"table_index": 24, "table_type": "financial", "caption": null, "header_text": "of\n SharesAmountofSharesAmountCapitalIncomeDeficitEquity"}, {"table_index": 25, "table_type": "financial", "caption": null, "header_text": "PreferredStockNumberPreferredStockCommonStockNumberCommonStockAdditionalPaid-in-AccumulatedOtherComprehensiveAccumulatedTotalStockholders\u2019Equity"}, {"table_index": 28, "table_type": "financial", "caption": null, "header_text": "20262025"}, {"table_index": 31, "table_type": "text", "caption": null, "header_text": "\u25cfLP-300\n (Tavocept), which we are advancing in a Phase 2 clinical trial, the Harmonic\u2122 trial, focused on never smokers with advanced\n non-small cell lung cancer;"}, {"table_index": 42, "table_type": "financial", "caption": null, "header_text": "2026202520262025"}, {"table_index": 45, "table_type": "financial", "caption": null, "header_text": "June 30,December 31,"}, {"table_index": 48, "table_type": "financial", "caption": null, "header_text": "June 30,December 31,"}, {"table_index": 49, "table_type": "financial", "caption": null, "header_text": ""}, {"table_index": 50, "table_type": "financial", "caption": null, "header_text": "OperatingOperating"}, {"table_index": 53, "table_type": "text", "caption": null, "header_text": "20262025"}, {"table_index": 54, "table_type": "financial", "caption": null, "header_text": "2026202520262025"}, {"table_index": 57, "table_type": "text", "caption": null, "header_text": "Warrants\n Issued and OutstandingWeightedAverageExercise PriceExercisableDateExpirationDate"}, {"table_index": 58, "table_type": "text", "caption": null, "header_text": "AThese warrants\nare subject to fair value accounting due to settlement features that may be triggered by a fundamental transaction. See Note 8 for fair value inputs."}, {"table_index": 61, "table_type": "text", "caption": null, "header_text": "Schedule\nof Stock Option ActivityOptions\n Outstanding"}, {"table_index": 62, "table_type": "text", "caption": null, "header_text": "2026202520262025"}, {"table_index": 65, "table_type": "financial", "caption": null, "header_text": "DescriptionTotalLevel\n 1Level\n 2Level\n 3"}, {"table_index": 66, "table_type": "text", "caption": null, "header_text": "DescriptionTotalLevel\n 1Level\n 2Level\n 3"}, {"table_index": 67, "table_type": "text", "caption": null, "header_text": "DescriptionPlacement\n Agent WarrantsPrivate\n Placement WarrantsTotal"}, {"table_index": 68, "table_type": "text", "caption": null, "header_text": "Placement\n Agent WarrantsIssued Duringthe Three andSix Months EndedJune 30, 2026As ofJune 30, 2026"}, {"table_index": 71, "table_type": "text", "caption": null, "header_text": "Private Placement\n WarrantsIssued Duringthe Three andSix Months EndedJune 30, 2026As ofJune 30, 2026"}, {"table_index": 72, "table_type": "text", "caption": null, "header_text": "20262025"}, {"table_index": 75, "table_type": "text", "caption": null, "header_text": "June\n 30, 2026December\n 31, 2025"}, {"table_index": 76, "table_type": "text", "caption": null, "header_text": "2026202520262025"}, {"table_index": 79, "table_type": "text", "caption": null, "header_text": "\u25cfCoordinated\n specialist agents spanning medicinal chemistry, computational biology, clinical trial strategy,\n biomarkers & translational science, clinical oncology, and general research."}, {"table_index": 86, "table_type": "financial", "caption": null, "header_text": "\u25cfexpenses\n incurred towards research and development employees, consultants, outside contractors, laboratories, clinical sites, and investigators\n that conduct our preclinical or clinical research act"}, {"table_index": 87, "table_type": "financial", "caption": null, "header_text": "Six MonthsSix Months"}, {"table_index": 88, "table_type": "financial", "caption": null, "header_text": "*withZeta.ai expenses relate to 2026"}, {"table_index": 91, "table_type": "financial", "caption": null, "header_text": "Three Months\n EndedSix Months\n Ended"}, {"table_index": 96, "table_type": "financial", "caption": null, "header_text": "For\n the Six MonthsEnded\n June 30,"}, {"table_index": 101, "table_type": "financial", "caption": null, "header_text": "\u25cfcontinue\n the development, including preclinical studies and clinical trials, of our drug candidates;"}, {"table_index": 102, "table_type": "text", "caption": null, "header_text": "\u25cfResearch\n and development;"}, {"table_index": 109, "table_type": "exhibit_index", "caption": null, "header_text": "Exhibit\n No.Exhibit\n DescriptionMethod\n of Filing"}, {"table_index": 112, "table_type": "text", "caption": null, "header_text": "Lantern\n Pharma Inc.,"}], "exhibits_pending": false, "cdn_html": true, "response_time_ms": 37}